Compare Quantum Computing Inc (QUBT) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quantum Computing Inc vs Repligen Corporation Common Stock — how do they compare? Quantum Computing Inc trades at $6.23 (market cap $1.56B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 7.1× Quantum Computing Inc's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Quantum Computing Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Quantum Computing Inc for 26 Days and Repligen Corporation Common Stock for 0 Days on average.
| QUBT | RGEN | |
|---|---|---|
Market Cap | $1.56B | $11.14B |
Volume | 6,616,227 | 1,259,263 |
Sector | Technology | Health |
52-Week High | $21.23 | $194.57 |
52-Week Low | $6.31 | $102.87 |
Typical Hold Time | 26 Days | 0 Days |
Enterprise Value | $621.96M | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quantum Computing Inc. (QUBT) trades at $6.87, down 0.87% on the day, with a bearish technical signal despite bullish oscillators. The company shows explosive revenue growth from $682K in 2025 to $10M projected for 2026, but remains deeply unprofitable with a -152.45% net margin. Recent developments include the Dirac-3S quantum system launch and a $42.5M backlog, though rising expenses and cash burn persist.
While analyst consensus is bullish with a $17.33 price target (75% buy ratings), QUBT faces significant execution risks as it scales quantum hardware production. The stock offers substantial upside potential if commercialization succeeds but carries high volatility given pre-profitability status and competitive quantum computing landscape.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
